Advertisement
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
437天前
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
471天前
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
618天前
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
1199天前
Hong Kong Shares Tipped To Open Under Pressure On Monday
The Hong Kong stock market had moved lower in five straight sessions, shedding almost 1,000 points or 3.6 percent along the way. The Hang Seng Index now sits just above the 26,290-point plateau and it may extend its slide on Monday.
RTTNews
|
8分鐘前
China Stock Market May Take Further Damage On Monday
The China stock market on Friday snapped the three-day winning streak in which it had climbed more than 100 points or 2.6 percent. The Shanghai Composite Index now rests just beneath the 3,900-point plateau and it's tipped to open in the red again on Monday.
RTTNews
|
23分鐘前
Australian Market Notably Higher
The Australian stock market is notably lower on Monday, adding to the slight losses in the previous session, following the broadly negative cues from Wall Street on Friday. The benchmark S&P/ASX 200 index is falling a tad below the 8,900.00 level, with weakness across most sectors led by energy and technology stocks. Gold was the only bright spot.
RTTNews
|
25分鐘前
Renewed Consolidation Likely For Taiwan Stock Market
Ahead of Friday's holiday for Double Tenth Day, the Taiwan stock market had moved higher again - one day after ending the five-day winning streak in which it had accelerated more than 1,630 points or 6.4 percent. The Taiwan Stock Exchange now sits just above the 27,300-point plateau although it may hand back those gains on Monday.
RTTNews
|
53分鐘前
